People: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

80.40CHF
23 Jul 2014
Price Change (% chg)

CHF-0.15 (-0.19%)
Prev Close
CHF80.55
Open
CHF80.40
Day's High
CHF80.45
Day's Low
CHF80.25
Volume
114,415
Avg. Vol
3,976,417
52-wk High
CHF81.70
52-wk Low
CHF65.70

Search Stocks

van Arkel, Paul 

Brief Biography

Mr. Paul van Arkel has been Head of Corporate Strategy and External Affairs at Novartis AG since May 2013. Prior to joining Novartis, Mr. van Arkel was a partner at McKinsey & Company, specializing in pharmaceuticals and medical products. At McKinsey, he led the company’s pharmaceutical marketing work in Europe, the Middle East, and Africa, as well as its work on pharmaceutical launches worldwide. Mr. van Arkel previously served as a consultant and later a partner at Monitor Group, initially focusing on corporate strategy across industries, and eventually moving to marketing and sales in pharmaceuticals and medical devices. Mr. van Arkel received a diploma in public administration from Leiden University in the Netherlands, and a master’s degree in business administration from Erasmus University, also in the Netherlands.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joerg Reinhardt

1,366,320

Joseph Jimenez

13,228,200

Ulrich Lehner

853,107

Harry Kirsch

--

Peter Kornicker

--

Felix Ehrat

3,584,790
As Of 30 Dec 2012
Search Stocks